THYROID GLAND CARCINOMA
Clinical trials for THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Matched conditions: THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Heat and radiation team up to fight spine cancer
Disease control OngoingThis study tests whether combining two treatments—thermal ablation (using heat to destroy tumor cells) and stereotactic radiosurgery (precise, high-dose radiation)—can better control cancer that has spread to the spine and is pressing on the spinal cord. About 60 adults with vari…
Matched conditions: THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New PET tracer could spot hidden cancers
Diagnosis OngoingThis early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…
Matched conditions: THYROID GLAND CARCINOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Matched conditions: THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 05:00 UTC